Monace Combi (Fosinopril Sodium, Hydrochlorothiazide)

• Monace Combi is an antihypertensive medication that lowers elevated blood pressure through combined ACE inhibition and diuresis.
• Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
• Essential hypertension: improves blood‑pressure control when monotherapy is insufficient.
• Fluid retention with hypertension: adds diuretic effect to manage excess volume and lower pressure.

• Fosinopril sodium blocks the angiotensin‑converting enzyme, decreasing formation of angiotensin II and leading to vasodilation. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of water and electrolytes. The combined actions reduce peripheral vascular resistance and blood volume, producing an additive antihypertensive effect.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Persistent dry cough.
• Headache.
• Increased frequency of urination.
• Mild electrolyte disturbances such as low potassium.
• Fatigue or general weakness.

Serious or Rare Side Effects

• Angioedema involving face, lips, tongue or airway.
• Severe dehydration or electrolyte imbalance.
• Hyperkalemia leading to cardiac rhythm changes.
• Acute kidney injury or sudden rise in serum creatinine.
• Marked hypotension causing fainting.
• Blood dyscrasias such as neutropenia or agranulocytosis.

Before initiating therapy, consider the following precautions:

• Monitor blood pressure regularly to assess efficacy.
• Check renal function and serum electrolytes before and during treatment.
• Avoid use in patients with severe renal impairment unless specifically directed.
• Use caution in diabetic patients as blood‑glucose levels may change.
• Assess for a history of angioedema or hypersensitivity to ACE inhibitors.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Monace Combi may interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment.
• Potassium‑containing supplements or salt substitutes.
• Lithium, which may reach toxic levels.
• Concurrent use of another ACE inhibitor or ARB.
• NSAIDs that can diminish renal protective effects.

Moderate Interactions (Monitor Closely)

• Other diuretics that may cause additive electrolyte loss.
• Additional antihypertensives leading to excessive blood‑pressure reduction.
• Antidiabetic agents that may require dose adjustment.
• Rifampin, which can lower fosinopril plasma concentrations.
• NSAIDs that may reduce the diuretic effect of hydrochlorothiazide.